A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone.
Aurinia will explore possible sale, following push by shareholder
Aurinia Pharmaceuticals said it will start exploring strategic alternatives, including a potential sale. The announcement follows calls by one of its major shareholders, MKT Capital.